Hot Pursuit     18-Mar-24
Zydus Life gains on USFDA nod for prostatic hyperplasia drug
Zydus Lifesciences rose 1.03% to Rs 994 after the company announced that it has received final approval from the United States Food and Drug Administration (USFDA) to market Finasteride and Tadalafil capsules USP.

“Zydus is the first approved applicant for Finasteride and Tadalafil capsules, 5 mg/5 mg, as defined in section 505(j)(5)(B)(v)(III) of the FD&C Act and therefore is eligible for 180 days of CGT exclusivity,” said the firm.

The said drug is used to treat benign prostatic hyperplasia and it is equivalent to reference listed drug, ENTADFI.

The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ II, India.

The group now has 392 approvals and has so far filed over 460 abbreviated new drug applications (ANDAs) since the commencement of the filing process in FY 2003-04.

Zydus Lifesciences is a discovery-driven, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.

The pharmaceutical company reported 26.76% increase in consolidated net profit of Rs 789.6 crore on 5.83% rise in revenue from operations to Rs 4,343.70 crore in Q3 FY24 over Q3 FY23.

Previous News
  Zydus Life’s Ahmedabad facility gets EIR from USFDA
 ( Hot Pursuit - 01-Oct-24   12:13 )
  Indices trade higher; consumer durable shares rally
 ( Market Commentary - Mid-Session 22-Apr-24   13:37 )
  Zydus receives USFDA approval for Valsartan Tablets
 ( Corporate News - 23-Jul-24   15:20 )
  Indices trade with moderate losses; PSU bank shares decline
 ( Market Commentary - Mid-Session 23-Jul-24   14:31 )
  Zydus' transdermal patch manufacturing facility completes USFDA inspection
 ( Corporate News - 01-Oct-24   12:26 )
  Zydus Life rises on USFDA nod for heart failure drug
 ( Hot Pursuit - 10-Jul-24   15:36 )
  Zydus Lifesciences receives USFDA tentative approval for Diroximel Fumarate Delayed-Release Capsules
 ( Corporate News - 10-Jul-24   16:03 )
  Zydus receives USFDA approval for Sacubitril and Valsartan Tablets
 ( Corporate News - 10-Jul-24   16:12 )
  Zydus Life edges higher after launching OAB treatment drug Mirabegron in US
 ( Hot Pursuit - 22-Apr-24   09:25 )
  Zydus receives USFDA final approval for Chlorpromazine Hydrochloride Injection
 ( Corporate News - 14-Mar-24   12:24 )
  Zydus receives USFDA tentative approval for Edaravone Injection
 ( Corporate News - 14-Mar-24   13:51 )
Other Stories
  UCO Bank’s total advances jump 19% YoY in Q2 FY25
  04-Oct-24   15:15
  Vakrangee Ltd leads losers in 'A' group
  04-Oct-24   15:00
  Kamdhenu Ventures Ltd leads losers in 'B' group
  04-Oct-24   14:45
  GRSE bags Rs 226-cr LoA from West Bengal Govt
  04-Oct-24   14:40
  Volumes soar at Avenue Supermarts Ltd counter
  04-Oct-24   14:30
  Real Estate stocks edge lower
  04-Oct-24   14:00
  Auto stocks edge lower
  04-Oct-24   14:00
  Utilties stocks edge lower
  04-Oct-24   14:00
  HDFC Bank Ltd down for fifth straight session
  04-Oct-24   13:35
  Power Grid Corporation of India Ltd down for fifth straight session
  04-Oct-24   13:35
Back Top